Supercharged MRI could reveal how prostate cancer reacts to radiation

NCT ID NCT06391034

Recruiting now Knowledge-focused Sponsor: Robert Bok, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of MRI scan that uses a special substance called hyperpolarized pyruvate to see how prostate cancer cells change during radiation therapy. About 161 men with prostate cancer will receive the substance through an IV before their regular MRI scans. The goal is to see if this technique can detect early signs of whether the cancer is responding to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hyperpolarized 13C-pyruvate and 13C,15N-urea
What this could lead to: If successful, this imaging method could help doctors see how prostate cancer responds to radiation therapy in real time, potentially guiding more personalized treatment.
What could go wrong: This is an early-phase imaging study, not a treatment trial. The new technique may not provide clearer results than standard scans, and it involves an intravenous injection of a contrast agent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.